Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Papillary adenocarcinoma
|
3 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||||
Penis carcinoma
|
3 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.010 | 1.000 | 1 | 2013 | 2013 | ||||||
Primary Lesion
|
8 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||||
Seborrheic keratosis
|
21 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.010 | 1.000 | 1 | 2014 | 2014 | ||||||
Secondary malignant neoplasm of liver
|
34 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||||
Secondary malignant neoplasm of lymph node
|
188 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.010 | 1.000 | 1 | 2012 | 2012 | ||||||
Secondary Neoplasm
|
85 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||||
Signs and Symptoms, Respiratory
|
10 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||||
Squamous cell carcinoma of lung
|
283 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||||
Squamous cell carcinoma of the head and neck
|
348 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.010 | 1.000 | 1 | 2012 | 2012 | ||||||
Stage IA Lung Adenocarcinoma AJCC v7
|
3 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||||
Stomach Carcinoma
|
652 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.010 | 1.000 | 1 | 2019 | 2019 | ||||||
Triple Negative Breast Neoplasms
|
99 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||||
Triple-Negative Breast Carcinoma
|
96 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||||
Tumor Progression
|
72 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.010 | 1.000 | 1 | 2012 | 2012 | ||||||
Adenocarcinoma, Tubular
|
3 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.020 | 1.000 | 2 | 2007 | 2018 | ||||||
Breast Carcinoma
|
2793 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.020 | 1.000 | 2 | 2013 | 2015 | ||||||
Carcinoma
|
103 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.020 | 1.000 | 2 | 2014 | 2015 | ||||||
Nodule
|
19 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.020 | 0.500 | 2 | 2015 | 2018 | ||||||
Non-small cell lung cancer recurrent
|
4 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.020 | 1.000 | 2 | 2015 | 2017 | ||||||
Non-squamous non-small cell lung cancer
|
4 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.020 | 1.000 | 2 | 2016 | 2018 | ||||||
Secondary malignant neoplasm of bone
|
18 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.020 | 1.000 | 2 | 2015 | 2017 | ||||||
Secondary malignant neoplasm of lung
|
20 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.020 | 1.000 | 2 | 2014 | 2016 | ||||||
Tumor Cell Invasion
|
169 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.020 | 1.000 | 2 | 2015 | 2018 | ||||||
Carcinogenesis
|
355 | 0.570 | 0.560 | 7 | 55191822 | missense variant | TG/GT | mnv | 0.030 | 0.667 | 3 | 2012 | 2016 |